☀ Morning Good News for Today
A non-invasive blood-flow analysis helped doctors avoid more invasive heart tests that found no obstructive disease. In the randomized FUSION trial, the encouraging result came from a carefully defined group of 528 people—not from a miracle headline or a promise of better health outcomes. [1][2]
Good news in 30 seconds
- FUSION randomized 528 Dutch patients with stable chest pain and a 50–90% narrowing seen in at least one coronary artery on CT imaging. [1][2][3]
- At 90 days, an invasive coronary angiogram found no obstructive disease in 18% of the CT-derived blood-flow group versus 33% of the usual-care group. [1][2]
- At one year, revascularization was 20% in each group. Quality of life, costs and major adverse cardiac events did not differ, and clinical-event counts were low. [1][2]
What happened
The investigator-initiated, multicenter FUSION trial studied people whose coronary CT angiography showed a 50–90% narrowing. Researchers randomly assigned 263 participants to care guided by computed-tomography-derived fractional flow reserve—usually shortened to FFRct—and 265 to usual care. [1][2]
FFRct uses the already captured CT images and software-based modeling to estimate how a narrowing affects blood flow. The trial’s primary question was narrow and practical: could that extra functional information reduce invasive angiograms that did not find obstructive coronary disease? [3]
At 90 days, the answer was encouraging. The rate was 18% in the FFRct-guided group and 33% with usual care—an odds ratio of 0.46, with the confidence interval and statistical test reported in the JACC abstract. [1]
A CT scan can show anatomy: where plaque and narrowing appear. The harder question is whether a particular narrowing meaningfully restricts blood flow. FFRct adds functional information without requiring a second invasive procedure just to obtain that estimate. [3]
This was a randomized trial with a prespecified clinical endpoint—not a funding announcement, a lab-only demonstration or a marketing survey. The narrower result also held at one year, while revascularization remained 20% in both groups. [1]
Why this made us smile
Sometimes the cheerful technology story is not a shiny new machine. It is better map-reading before taking the invasive route. In this trial, software helped clinicians ask one more useful question of an existing scan before sending everyone down the same road.
What it could mean for everyday people
For patients who resemble the FUSION participants, the result suggests that CT-derived blood-flow information may help a care team decide who is more likely to need invasive coronary angiography. That could mean fewer people undergoing a catheter-based diagnostic procedure only to learn that no obstructive disease was found.
The practical phrase is may help. The trial does not tell any individual to undergo or defer testing, and it does not replace a clinician’s judgment, symptoms, medical history or discussion with the patient. Availability, reimbursement and workflow outside the Dutch trial remain open questions.
Keep the confetti factual
This is a positive diagnostic-efficiency result—not proof of better survival, fewer heart attacks, improved quality of life, lower costs or guaranteed safety. The JACC abstract says quality of life, costs and major adverse cardiac events did not differ, while clinical-event rates were low. Its analysis of overall angiogram use was post-hoc and exploratory rather than the prespecified primary endpoint. [1][2]
The findings also apply to a selected Dutch population with stable chest pain and 50–90% stenosis on CT—not automatically to unstable symptoms, different stenosis ranges, previous revascularization or scans unsuitable for the analysis. ClinicalTrials.gov still showed an older recruiting record with no posted results at our cutoff, so we used it for protocol and eligibility context, not as evidence of the new results. [3]
One happy thing to carry with you
Progress does not always mean doing more procedures. Sometimes it means getting more useful information from the scan already on the screen—and choosing the next step with a little more clarity.
Sources and reporting notes
- JACC — FUSION randomized controlled trial abstract (published online August 28, 2026)
- American College of Cardiology — independent JACC studies summary (August 29, 2026)
- ClinicalTrials.gov — FUSION protocol and eligibility record (NCT05174247)
- Heartflow — official FUSION results announcement (August 28, 2026; company source)